APRE
Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Aprea Therapeutics serves customers in the United States and Sweden.
Aprea Therapeutics, Inc. (APRE) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | D+ (1.8) | D+ (1.6) | D (1.3) | D+ (1.6) | C+ (2.6) | D+ (1.8) |
| 2026-11-10 | C- (1.9) | D+ (1.8) | D (1.3) | D+ (1.8) | C+ (2.6) | C- (1.9) |
| 2026-11-03 | D+ (1.8) | D+ (1.5) | D (1.3) | C (2.2) | C+ (2.7) | C- (1.9) |
| 2026-10-27 | D+ (1.8) | D+ (1.5) | D (1.3) | C- (1.9) | C+ (2.6) | D+ (1.8) |
| 2026-10-20 | D+ (1.8) | D+ (1.5) | D (1.3) | C- (1.9) | C+ (2.6) | D+ (1.8) |